Working Remotely Through COVID-19

by | Mar 25, 2020 | CDC, Coronavirus, EU MDR, OQA, QMS, Quality Systems, Requirements

With the number of confirmed COVID-19 cases now exceeding 200,000 globally, the WHO and many other international government agencies are either recommending or enforcing a “shelter in place” order to slow the spread of the disease.1 This is an unprecedented time for the medical device and other life-science industries as they must adapt to 100% remote work quickly. With the EU MDR deadline still set for May 26th, the global shortage of medical devices, and other obstacles still to come, the medical device industry can’t afford to skip a beat.

EMMA International’s Outsourced Quality Assurance (OQA) Program® can oversee your Quality Management System (QMS) and is a flexible and efficient way to outsource all your QA/RA needs 100% remotely. The focus right now is getting all critical medical devices to the hospitals and patients that need them, which means QA/RA work will only continue to ramp up in the face of this public health emergency. As medical device institutions face travel restrictions, the challenge of adapting to remote work, and other upheavals, EMMA International’s OQA Program® can step in and ensure seamless integration.

In this new era of working from home, having expert talent available anytime is crucial. EMMA’s OQA Program® has an unparalleled deployment speed and scalability, with a team of Quality and Regulatory experts ready to jump in. Our OQA Program® ensures that whatever your needs are, we have a solution tailored to you which includes:

  • A team of internal experts with the experience and credentials suited for any quality or regulatory needs.
  • Availability when and where you need it.
  • Proven project management expertise, to ensure no matter the situation you won’t miss a deadline.
  • Flexibility to the ever-changing priorities and regulations, especially surrounding COVID-19.

The COVID-19 pandemic is forcing the medical device industry to re-think how they can support their QA/RA functions. With an unprecedented time still ahead of us, give EMMA International a call at 248-987-4497 or email info@emmainternational.com to see how we can suit our OQA Program® to fit your needs through it.

To learn more about what our OQA Program® has to offer, visit https://emmainternational.com/outsourced-quality-assurance/


1WHO (March 2020) Coronavirus disease 2019 situation report – 59 retrieved on 03/20/2020 from: https://www.who.int/docs/default-source/coronaviruse/situation-reports/20200319-sitrep-59-covid-19.pdf?sfvrsn=c3dcdef9_2

Madison Wheeler

Madison Wheeler

Director of Technical Operations - Ms. Wheeler serves as EMMA International’s Director of Technical Operations. She has experience in technical writing, nonconforming product management, issue evaluations, and implementing corrective and preventative actions in the pharmaceuticals and medical device industries. She has experience cross-functionally between R&D, lean manufacturing operations, and RA compliance. Ms. Wheeler also has academic and work experience with human health-risk engineering controls, physiological biophysics, and clinical research. Ms. Wheeler holds a Bachelor of Science in Biosystems Engineering with a concentration in Biomedical Engineering from Michigan State University. She is also a Certified Quality Auditor (CQA), and is currently pursuing her M.S. in Quality Management.

More Resources

FDA’s Refusal to Accept Process

FDA’s Refusal to Accept Process

Before the submission of a 510(k) premarket notification, the purpose of which is to notify the FDA of the manufacturer’s intent to market a medical device,[i] there is a provision for acceptance review. This review serves as a method to assess whether a submission is administratively complete and includes all necessary information for FDA to determine substantial equivalence under section 513(i) of the Federal Food, Drug, and Cosmetic (FD&C) Act (21 United States Code (U.S.C.) § 360c(i)). To establish substantial equivalence under this provision, FDA must find the same intended use as the predicate device and either have the same technological characteristics as the predicate device or appropriate clinical and scientific data necessary to establish that the device is safe and effective as the predicate device. If the Authority is unable to determine substantial equivalence due to insufficient information, it may request for additional information to make that determination. Therefore, as a part of the acceptance review, the FDA staff follows the acceptance checklist[ii] to ensure that the application is administratively complete. These administrative elements are identified as RTA items and are required to be presented. The purpose of conducting the acceptance review is for the Lead Reviewer to determine whether the 510(k) submission meets the minimum threshold of acceptability and should be accepted for substantive review.[iii]
Empowering Your Workforce through Kaizen

Empowering Your Workforce through Kaizen

Last week, I touched on the idea of involving and empowering all employees in the workplace through the corrective and preventive actions process by fostering taking initiative and a problem-solving (refer to blogpost ‘The Art of Addressing Non-Conformances in Operations’). To expand on this concept a bit further, we’re going to be looking at Kaizen–a continuous improvement strategy in which employees at all levels are also empowered to solve problems towards big gains.
FDA’s draft guidelines on Remote Regulatory Assessments (RRAs)

FDA’s draft guidelines on Remote Regulatory Assessments (RRAs)

The pandemic has been a challenging time for all industries including the Food and Drug Administration (FDA). The FDA had to alter the manner in which it conducted its operations. One set of tools adopted by the FDA in response to COVID-19 was the remote regulatory assessment (RRAs).

Ready to learn more about working with us?

Pin It on Pinterest

Share This